Pedro P Ylisastigui

119. Safety and Reactogenicity of an Investigational Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine for Adults ≥ 60 Years of Age (RSVPreF3 OA): an Interim Analysis at 6 Months after Vaccination

Shinn-Jang Hwang, M. Lievens, C. Liu, 2022, Open Forum Infectious Diseases.

96. A Candidate Respiratory Syncytial Virus (RSV) Prefusion F Protein Investigational Vaccine (RSVPreF3 OA) Is Immunogenic when Administered in Adults ≥ 60 Years of Age: Results at 6 Months after Vaccination

Shinn-Jang Hwang, M. Lievens, C. Liu, 2022, Open Forum Infectious Diseases.